Cannara Biotech Reports Q3 2024 Financial Results
Cannara Biotech (TSXV: LOVE, OTCQB: LOVFF) reported financial results for Q3 2024, showcasing impressive growth in revenues but a decline in profitability. Gross cannabis revenues rose 27.6% to $26.2 million, up from $20.6 million in Q3 2023. Total revenues, net of excise taxes, reached $19.5 million, marking a 22.6% increase. However, gross profit before fair value adjustments fell 6.1% to $5.7 million, with profitability impacted by cultivation changes. Despite industry price compression, Cannara reported its thirteenth consecutive quarter of positive Adjusted EBITDA at $2.8 million and net income of $2.0 million. Operating income stood at $3.6 million, buoyed by a $2 million gain from the sale of unused land.
Operational highlights include entering the Manitoba market, launching new genetics, and expanding in Quebec. Financial highlights show increased free cash flow to $1.2 million and earnings per share at $0.02. The company continues to invest in sales and marketing to capture more market share.
- Gross cannabis revenues increased by 27.6% to $26.2 million.
- Total revenues, net of excise taxes, increased by 22.6% to $19.5 million.
- Thirteenth consecutive quarter of positive Adjusted EBITDA at $2.8 million.
- Operating cash flow rose by 72% to $4.3 million.
- Free cash flow increased to $1.2 million from ($37,000) in Q3 2023.
- Entered Manitoba market and launched new genetics.
- Gross profit before fair value adjustments decreased by 6.1% to $5.7 million.
- Gross profit percentage before fair value adjustments fell to 29% from 38%.
- Operating income decreased to $3.6 million from $4.3 million.
- Net income decreased to $2.0 million from $2.9 million.
- Adjusted EBITDA dropped to $2.8 million from $3.9 million.
- Earnings per share decreased to $0.02 from $0.03.
Gross cannabis revenues before excise taxes increased to
Total revenues, net of excise taxes, increased to
Delivered a thirteenth consecutive quarter of positive Adjusted EBITDA1 of
All financial results are reported in Canadian dollars, unless otherwise stated.
MONTREAL, July 23, 2024 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. ("Cannara" or the "Company") (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB0), a vertically integrated producer of premium-grade cannabis and derivative product offerings at affordable prices with two mega facilities based in Quebec spanning over 1,650,000 sq. ft., today announced its fiscal third quarter 2024 financial and operating results for the three and nine-month periods ended May 31, 2024. The full set of Condensed Interim Consolidated Financial Statements for the three and nine-month periods ended May 31, 2024, and the accompanying Management’s Discussion and Analysis can be accessed by visiting the Company’s website at https://www.cannara.ca/en/investor-area or by accessing its profile pages on SEDAR+ at www.sedarplus.ca.
"We're delighted to share that Cannara continues to show strong performance, with net revenues reaching
"The cannabis industry is navigating a highly competitive landscape with significant price compression due to challenging conditions," stated Nicholas Sosiak, Chief Financial Officer of Cannara. "Despite these pressures, Cannara's resilience is evident in our increased net revenues of
Third Quarter Financial Highlights
- Gross cannabis revenues before excise taxes increased to
$26.2 million in Q3 2024 from$20.6 million in Q3 2023, a$5.6 million or27.6% , increase. The increase is attributable to Cannara’s entrance into new provinces in Canada, as well as the launch of several new SKUs and sales generated from the wholesale market. - Total revenues, net of excise taxes, increased to
$19.5 million in Q3 2024 from$15.9 million in Q3 2023, a$3.6 million or22.6% increase. - Gross profit, before fair value adjustments, decreased to
$5.7 million in Q3 2024 from$6.1 million in Q3 2023, representing a6.1% decline. This decrease was primarily due to a reduction in yields resulting from cultivation changes implemented during Q2 2024, which impacted the cost of goods sold in Q3 2024. During the quarter, the Company reversed these changes and focused on stabilizing its production yields, successfully restoring them to previous levels. Cannara is dedicated to advancing research and development, harnessing our expertise to strengthen the knowledge and core competencies in large-scale cannabis production. Through these ongoing investments, we aim to consistently elevate our cultivation techniques, maximize production yields, and enhance the overall quality of our products. - Gross profit percentage before fair value adjustments in Q3 2024 was
29% compared to38% in Q3 2023. - Operating income of
$3.6 million in Q3 2024 compared to$4.3 million in Q3 2023, mainly due to an increased costs of goods sold this quarter as mentioned above, as well as increases in selling and marketing expenses to promote and grow our market share across Canada. These impacts were reduced by a gain of$2 million resulting from the sale of a parcel of unused land at the Valleyfield site. - Net income of
$2.0 million in Q3 2024 compared to$2.9 million in Q3 2023, as a result of the items mentioned above. - Adjusted EBITDA of
$2.8 million in Q3 2024, compared to$3.9 million in Q3 2023. - The Company generated operating cash flow amounting to
$4.3 million in Q3 2024 compared to$2.5 million in Q3 2023, an increase of72% . - Free cash flow2 for Q3 2024 increased to
$1.2 million from ($37,000) in Q3 2023. - Generated earnings per share of
$0.02 in Q3 2024 compared to$0.03 in Q3 2023.
Third Quarter Operational Highlights
Expansion in Manitoba, Canada: In March 2024, the Company secured authorization from the Manitoba Liquor & Lotteries Corporation (MBLL) to introduce its branded cannabis products within the province of Manitoba. This approval marks a significant milestone in Cannara’s expansion efforts, allowing the Company to extend its market reach in Canada. The Company successfully completed its first sale into Manitoba at the end of May 2024 with 35 listings.
Successful Launch of 3 New Genetics for Cannara’s House of Brands: Cannara completed its most recent pheno-hunt program, unlocking 3 new high-powered genetics for its house of brands. The Company launched two genetics under Tribal (Neon Sunshine and Bubble Up) and one under Nugz (Guava Jam) in Q3 2024. Cannara is now focused on its FY 2025 pheno-hunt program that will aim to unlock more exotic genetics.
Sale of Parcel of Land at Valleyfield Site: In January 2024, the Company’s Board of Directors decided to pursue the sale of a currently unused parcel of land, in addition to an adjacent building under construction at its Valleyfield site, which had previously been intended to be leased out. On April 24, 2024, the Company sold the parcel of land at the Valleyfield Facility for
Cannara enters East Coast Recreational Market With 4/20-Themed Offer with NSLC: Cannara successfully launched its consumer favourite Tribal Cuban Linx pre-rolls with the Nova Scotia Liquor Corporation (NSLC) for a 4/20-themed holiday limited time offer. As a result of its success, the NSLC has now accepted the SKU, in addition to a 28g offering of Cuban Linx set to launch in early Fall 2024 as general listings, with more SKUs to be accepted in the quarters to come.
Continued Expansion in Quebec and Other Provinces: Cannara’s continued efforts to develop a unique portfolio of brands, tailored to appeal to consumers across various categories, demonstrated positive consumer response in the third quarter of 2024. Notably, in Quebec, according to Weedcrawler data, the Company saw a
Capital Transactions
During the third quarter of 2024, the Company granted 25,000 stock options at an exercise price of
Outstanding Shares
As at the date of this news release, the Company had 90,018,952 common shares, 4,549,927 stock options and 1,504,183 RSUs issued and outstanding. For further information, the complete Condensed Interim Consolidated Financial Statements and Management’s Discussion and Analysis, along with additional information about the Company and all of its public filings that by visiting the Company’s website at https://www.cannara.ca/en/investor-area or by accessing its profile pages on SEDAR+ at www.sedarplus.ca.
SELECTED FINANCIAL INFORMATION
| Three-month periods ended | Nine-month periods ended | ||||||||||||
| Selected Financial Highlights | May 31, 2024 | May 31, 2023 | May 31, 2024 | May 31, 2023 | |||||||||
| Net revenue 1 | $ | 19,475,137 | $ | 15,840,140 | $ | 58,563,040 | $ | 38,929,458 | |||||
| Other income | 69,779 | 96,688 | 148,373 | 354,731 | |||||||||
| Total revenues | 19,544,916 | 15,936,828 | 58,711,413 | 39,284,189 | |||||||||
| Gross profit, before fair value adjustments | 5,747,047 | 6,120,878 | 20,824,040 | 14,174,905 | |||||||||
| Gross profit | 6,958,256 | 8,594,235 | 19,334,110 | 17,688,552 | |||||||||
| Operating expenses | 3,404,212 | 4,311,958 | 14,300,967 | 11,632,065 | |||||||||
| Operating income | 3,554,044 | 4,282,277 | 5,033,143 | 6,056,487 | |||||||||
| Net finance expense | 1,530,658 | 1,353,634 | 4,349,098 | 3,742,948 | |||||||||
| Net income | 2,023,386 | 2,928,643 | 684,045 | 2,313,539 | |||||||||
| Adjusted EBITDA 2 | 2,776,397 | 3,887,634 | 11,447,529 | 8,825,357 | |||||||||
| Percentages of Total revenues | |||||||||||||
| Gross profit, before fair value adjustments as a percentage of Total revenues 3 | 29 | % | 38 | % | 35 | % | 36 | % | |||||
| Gross profit as a percentage of Total revenues 4 | 36 | % | 54 | % | 33 | % | 45 | % | |||||
| Operating income as a percentage of Total revenues 5 | 18 | % | 27 | % | 9 | % | 15 | % | |||||
| Net income as a percentage of Total revenues 6 | 10 | % | 18 | % | 1 | % | 6 | % | |||||
| Adjusted EBITDA as a percentage of Total revenues 7 | 14 | % | 24 | % | 19 | % | 22 | % | |||||
| Earnings per share | |||||||||||||
| Basic earning per share | $ | 0.02 | $ | 0.03 | $ | 0.01 | $ | 0.03 | |||||
| Diluted earning per share | $ | 0.02 | $ | 0.03 | $ | 0.01 | $ | 0.03 | |||||
| May 31, 2024 | August 31, 2023 | ||||||||||||
| Cash | $ | 5,464,378 | $ | 4,270,517 | |||||||||
| Accounts receivable | 11,829,419 | 10,592,705 | |||||||||||
| Biological assets | 4,852,449 | 5,774,121 | |||||||||||
| Inventory | 32,603,729 | 27,997,589 | |||||||||||
| Working capital 8 | 35,242,622 | 30,513,009 | |||||||||||
| Total assets | 148,768,302 | 141,522,254 | |||||||||||
| Total current liabilities | 26,777,902 | 21,182,827 | |||||||||||
| Total non-current liabilities | 40,222,572 | 40,595,383 | |||||||||||
| Net assets | 81,767,828 | 79,744,044 | |||||||||||
| Free cash flow 9 | 1,242,527 | 1,107,464 | |||||||||||
| 1 | Net revenue included revenue from sale of goods, net of excise taxes, services revenues and lease revenues. |
| 2 | Adjusted EBITDA is a non-GAAP financial measure. |
| 3 | Gross profit before fair value adjustments as a percentage of Total revenues is a non-GAAP financial ratio. For more details see the Non-GAAP and Other Financial Measures section of this news release. |
| 4 | Gross profit as a percentage of Total revenues is a non-GAAP financial ratio. For more details see the Non-GAAP Measures section of this news release. |
| 5 | Operating income as a percentage of Total revenues is a non-GAAP financial ratio. For more details see the Non-GAAP Measures section of this news release. |
| 6 | Net income as a percentage of Total revenues is a non-GAAP financial ratio. For more details see the Non-GAAP Measures section of this news release. |
| 7 | Adjusted EBITDA as a percentage of Total revenues is a non-GAAP financial ratio. For more details see the Non-GAAP Measures section of this news release. |
| 8 | Working capital is a non-GAAP financial measure. For more details see the Non-GAAP Measures section of this news release |
| 9 | Free cash flow is a non-GAAP financial measure. For more details see the Non-GAAP Measures section of this news release. |
Non-GAAP Measures, Non-GAAP Ratios and Segment Measures
The Company reports its financial results in accordance with International Financial Reporting Standards (“IFRS”). Cannara uses a number of financial measures when assessing its results and measuring overall performance. Some of these financial measures are not calculated in accordance with IFRS. National Instrument 52-112 respecting Non-GAAP and Other Financial Measures Disclosure (“NI 52-112”) prescribes disclosure requirements that apply to the following types of measures used by the Company: (i) non-GAAP financial measures (ii) non-GAAP financial ratios and (iii) total of segments measures. In this news release, the following non-GAAP measures, non-GAAP ratios and segment measures are used by the Company: adjusted EBITDA, free cash flow, working capital, segment gross profit before fair value adjustments as a percentage of segment net revenue, segment gross profit as a percentage of segment net revenue, segment operating income as a percentage of segment net revenue, and adjusted EBITDA as a percentage of net revenue. There are no total of segments measures included in this press release. Additional details for these non-GAAP and other financial measures can be found in the section entitled “Non-GAAP Financial Measures, Non-GAAP Ratios and Segment Measures” of Cannara’s MD&A for the three and nine-months ended May 31, 2024, which is posted on Cannara’s website at www.cannara.ca and filed on SEDAR+ at www.sedarplus.ca. Reconciliations of non-GAAP financial measures and non-GAAP ratios to the most directly comparable IFRS measures are provided below. Management believes that these non-GAAP financial measures and non-GAAP ratios provide useful information to investors regarding the Company’s financial condition and results of operations as they provide key metrics of its performance. These measures are not recognized under IFRS, do not have any standardized meanings prescribed under IFRS and may differ from similar computations as reported by other issuers, and accordingly may not be comparable. These measures should not be viewed as a substitute for the related financial information prepared in accordance with IFRS.
Reconciliation of Adjusted EBITDA
Adjusted EBITDA is a non-GAAP Measure and can be reconciled with net income, the most directly comparable IFRS financial measure, as detailed below. Management has changed the composition of Adjusted EBITDA since the second quarter of 2024 to add the gain on disposal of asset held for sale in the adjustments made to calculate the EBITDA. These changes are intended to allow investors and analysts to understand Company's operational performance by excluding non-recurring transactions.
Adjusted EBITDA as a percentage of Total revenues is a non-GAAP financial ratio, determined as adjusted EBITDA divided by total revenues.
| Three-month periods ended | Nine-month periods ended | ||||||||||||
| Reconciliation of adjusted EBITDA | May 31, 2024 | May 31, 2023 | May 31, 2024 | May 31, 2023 | |||||||||
| Net income | $ | 2,023,386 | $ | 2,928,643 | $ | 684,045 | $ | 2,313,539 | |||||
| Adjustments: | |||||||||||||
| Changes in fair value of inventory sold | 5,137,341 | 4,023,826 | 17,161,049 | 9,971,578 | |||||||||
| Unrealized gain on changes in fair value of biological assets | (6,348,550 | ) | (6,497,183 | ) | (15,671,119 | ) | (13,485,225 | ) | |||||
| Amortization, including amortization of cost of goods sold | 1,785,153 | 1,187,620 | 4,134,592 | 2,918,501 | |||||||||
| Write-down of inventory to net realizable value | 283,244 | 474,654 | 1,206,613 | 1,886,363 | |||||||||
| Gain on disposal of asset held for sale | (2,039,007 | ) | - | (2,039,007 | ) | - | |||||||
| Loss on disposal of property, plant and equipment | - | - | 5,380 | 63,247 | |||||||||
| Share-based compensation | 404,172 | 416,440 | 1,616,878 | 1,414,406 | |||||||||
| Net finance expense | 1,530,658 | 1,353,634 | 4,349,098 | 3,742,948 | |||||||||
| Adjusted EBITDA* | $ | 2,776,397 | $ | 3,887,634 | $ | 11,447,529 | $ | 8,825,357 | |||||
| Adjusted EBITDA as a percentage of Total revenues** | 14 | % | 24 | % | 19 | % | 22 | % | |||||
*Non-GAAP financial measure
**Non-GAAP financial ratio
Reconciliation of Free Cash Flow
Free cash flow is a non-GAAP measure and can be reconciled with cash from operating activities, the most directly comparable IFRS financial measure, as detailed below.
| Three-month periods ended | Nine-month periods ended | ||||||||||||
| Reconciliation of free cash flow | May 31, 2024 | May 31, 2023 | May 31, 2024 | May 31, 2023 | |||||||||
| Cash from operating activities | $ | 4,325,380 | $ | 2,540,852 | $ | 7,496,392 | $ | 3,023,289 | |||||
| Adjustment: | |||||||||||||
| Capital expenditures | 3,082,853 | 2,577,685 | 6,975,869 | 8,099,061 | |||||||||
| Free cash flow* | $ | 1,242,527 | $ | (36,833 | ) | $ | 520,523 | $ | (5,075,772 | ) | |||
*Non-GAAP financial measure
Reconciliation of working capital
Working capital is a non-GAAP Measure and can be reconciled with total current assets and total current liabilities, the most directly comparable GAAP financial measure, as detailed below.
| As at | As at | |||||
| Reconciliation of working capital | May 31, 204 | August 31, 2023 | ||||
| Total current assets | $ | 62,020,524 | $ | 51,695,836 | ||
| Total current liabilities | 26,777,902 | 21,182,827 | ||||
| Working capital* | $ | 35,242,622 | $ | 30,513,009 | ||
*Non-GAAP financial measure
Contact:
Nicholas Sosiak, CPA, CA
Chief Financial Officer
nick@cannara.ca
Zohar Krivorot
President & Chief Executive Officer
zohar@cannara.ca
About Cannara Biotech Inc.
Cannara Biotech Inc. (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB0), is a vertically integrated producer of affordable premium-grade cannabis and cannabis-derivative products for the Canadian markets. Cannara owns two mega facilities based in Québec spanning over 1,650,000 sq. ft., providing the Company with 100,000 kg of potential annualized cultivation output. Leveraging Québec’s low electricity costs, Cannara’s facilities produce premium-grade cannabis products at an affordable price. For more information, please visit https://www.cannara.ca/en/.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Statement Regarding “Forward-Looking” Information
This news release may contain “forward-looking information” within the meaning of applicable securities legislation (“forward-looking statements”). These forward-looking statements are made as of the date of this news release and the Company does not intend, and does not assume any obligation, to update these forward-looking statements, except as required under applicable securities legislation. Forward-looking statements relate to future events or future performance and reflect Company management’s expectations or beliefs regarding future events and include, but are not limited to, the Company and its operations, its projections or estimates about its future business operations, its planned expansion activities, the adequacy of its financial resources, the ability to adhere to financial and other covenants under lending agreements, future economic performance, and the Company’s ability to become a leader in the field of cannabis cultivation, production, and sales.
In certain cases, forward-looking statements can be identified by the use of words such as “plans,” “expects” or “does not expect,” “is expected,” “budget,” “scheduled,” “estimates,” “forecasts,” “intends,” “anticipates” or “does not anticipate,” or “believes,” or variations of such words and phrases or statements that certain actions, events or results “may,” “could,” “would,” “might” or “will be taken,” “occur” or “be achieved” or the negative of these terms or comparable terminology. In this document, certain forward-looking statements are identified by words including “may,” “future,” “expected,” “intends” and “estimates.” By their very nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.
Such factors include, but are not limited to, the factors discussed in the section “Risk Factors” of the MD&A as well as those factors detailed from time to time in the Company’s interim and annual financial statements and the related MD&A of those statements. Although the Company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended.
The Company provides no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Historical results of operations and trends that may be inferred from the following discussions and analysis may not necessarily indicate future results from operations.
1 Adjusted EBITDA is a non-GAAP financial measure. For more details see the Non-GAAP Measures, Non-GAAP Ratios and Segment Measures section of this news release.
2 Free cash flow is a non-GAAP financial measure. For more details see the Non-GAAP Measures, Non-GAAP Ratios and Segment Measures section of this news release.
3 Based on estimated sales data provided by Weed Crawler and ST Analytics, for the period of June 2024.
FAQ
What were Cannara Biotech's gross cannabis revenues in Q3 2024?
How much did Cannara Biotech's total revenues increase in Q3 2024?
What was Cannara Biotech's Adjusted EBITDA in Q3 2024?
What was the net income for Cannara Biotech in Q3 2024?
What led to the decrease in Cannara Biotech's gross profit in Q3 2024?
How did Cannara Biotech’s free cash flow change in Q3 2024?
What was Cannara Biotech's earnings per share in Q3 2024?
